Miglustat
Who holds supplier records for Miglustat? 4 organisations hold a current record for Miglustat: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: Switzerland (1), India (1) and United States (1); not recorded for 1.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Miglustat: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/miglustat
Reading the evidence
- 4 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 1 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Miglustat expires 16 Sept 2038. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (4)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Miglustat. Country is the organisation's recorded country, not necessarily the manufacturing site.
- APICORE LLC (A WHOLLY OWNED SUB OF RK PHARMA INC)Active DMF 41867 · latest filing Jun 2025
- DIPHARMA SASwitzerland Company GMP cert on recordActive DMF 29329 · latest filing Jun 2015
- MATRIX PHARMACORP PRIVATE LTDIndiaActive DMF 26294 · latest filing Mar 2013
- NAVINTA LLCUnited StatesActive DMF 36453 · latest filing Nov 2021
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (5 listed products contain Miglustat). The latest listed patent expires 16 Sept 2038. The latest listed exclusivity ended 28 Sept 2026. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Miglustat is an oral drug used primarily for the treatment of type 1 Gaucher disease and Niemann-Pick disease type C. It functions by inhibiting the enzyme glucosylceramide synthase, reducing the substrate accumulation that characterizes these disorders.
Chemical identity
- IUPAC name
- (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
- Canonical SMILES
- CCCCN1C[C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O
- InChIKey
- UQRORFVVSGFNRO-UTINFBMNSA-N
- Synonyms
- Zavesca API, 1,5-(butylimino)-1,5-dideoxy-d-glucitol, butyldeoxynojirimycin, n-butyldeoxynojirimycin, ogt-918, opfolda, zavesca
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Enzyme Stabilizer; Glucosylceramide Synthase Inhibitor
- Mechanism of action
- Enzyme Stabilizers; Glucosylceramide Synthase Inhibitors
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Miglustat?
4 organisations hold an active US FDA Type II Drug Master File or a CEP for Miglustat: APICORE LLC (A WHOLLY OWNED SUB OF RK PHARMA INC), DIPHARMA SA (Switzerland), MATRIX PHARMACORP PRIVATE LTD (India) and NAVINTA LLC (United States). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Miglustat Drug Master Files are active?
APICORE LLC (A WHOLLY OWNED SUB OF RK PHARMA INC) (DMF 41867), DIPHARMA SA (DMF 29329), MATRIX PHARMACORP PRIVATE LTD (DMF 26294) and NAVINTA LLC (DMF 36453). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
Does the FDA Orange Book list patents for products containing Miglustat?
Yes. The latest patent listed for an approved US product containing Miglustat expires 16 Sept 2038, across 5 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Miglustat supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Miglustat?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.